Skip to content

Study · Non-randomized trial · n = 8 · 1991

1 result

Paradoxical response of growth hormone to peptide histidine methionine in acromegaly: comparison with the effects of thyrotropin-releasing hormone and vasoactive intestinal peptide.

Watanobe H, Sasaki S, Sone K, Takebe K

The Journal of clinical endocrinology and metabolism1 May 1991Cited by 10 (Europe PMC)

PMID1902488 (opens in a new tab)DOI10.1210/jcem-72-5-982 (opens in a new tab)PepBankPUB-01902488
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In eight patients with active acromegaly, VIP caused a paradoxical rise in plasma growth hormone of more than 50% above baseline in five patients.

    In plain wordsIn eight patients with acromegaly, VIP caused an unexpected rise in growth hormone in five patients.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseParadoxical GH rise after VIP in acromegaly
    Study

    n = 8

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 microgramsAs given in this study (human).

    Source sentences

    Summary
    A paradoxical rise (greater than 50% above the basal) in plasma GH was observed in five patients after both TRH and VIP administrations
    2 context sentences
    Summary · context
    vasoactive intestinal peptide (VIP, 100 micrograms)
    Summary · context
    PHM (100 micrograms) was given as an iv bolus to eight patients with active acromegaly, and plasma GH levels were measured before and at intervals up to 120 min after the injection.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.